Biotech Startups

Hyris provides diagnostic testing solutions and marketplace technology for healthcare facilities and agricultural operations, enabling distributed testing networks managed from a central hub and pathogen detection services.

1 investor

Intrinsic Foundries engineers biological systems to convert carbon emissions into valuable feedstock, targeting industrial sectors where carbon is generated in high volumes. The company applies synthetic biology and bioengineering to transform waste carbon into wealth at scale.

1 investor

Ikonopedia provides a breast imaging software platform for radiologists and patients, featuring structured reporting tools, risk assessment, and closed-loop lesion tracking to ensure comprehensive breast health management and follow-up care.

1 investor

i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases. It co-creates and invests in biotech startups, operating as part of the Expert Systems integrated accelerator platform.</parameter> <parameter name="hq_city">San Diego

1 investor

Fluidics designs and manufactures customized microparticles and capsules for businesses requiring specialized formulations, leveraging in-house capabilities for active protection, controlled release, and formulation enhancement.

1 investor

IBI SA (Industrie Biomediche Insubri SA) researches, develops, and produces medical devices for tissue engineering and regenerative medicine, including bone substitutes, grafts, 3D matrixes, and 2D scaffolds.

1 investor

ICBII develops molecular technology platforms designed to deliver therapeutic molecules across the blood-brain barrier to treat neurodegenerative diseases such as Parkinson's and Alzheimer's. The company focuses on advancing drug delivery capabilities for treating major diseases affecting the central nervous system.

1 investor

Ichora develops crop protection fungicide solutions using repurposed molecules with antimicrobial properties to address resistant plant pathogens. The company targets agricultural producers seeking effective alternatives to conventional fungicides.

1 investor

Ickler Electric is an electrical contracting firm with 35 years of experience serving the biotech, electronics, and mission-critical industries. The company performs complex electrical construction and installation projects with in-house engineering, CAD/BIM design, prefabrication, and service capabilities.

1 investor

Icon Bioscience develops biodegradable, sustained-release intraocular ophthalmic products using its proprietary Verisome drug delivery technology, targeting unmet needs in inflammation, glaucoma, and retinal disease treatment.

1 investor

1 investor

Iconovo develops advanced inhaler platforms and dry powder formulations optimized together to deliver medicines through inhalation across multiple therapeutic areas. The company partners with pharmaceutical manufacturers to create effective alternatives to tablets and injections, generating revenue through development partnerships, milestone payments, and royalties.

1 investor

ICON plc is a global Contract Research Organization providing consulting and outsourced development services to pharmaceutical, biotechnology, medical device, and government organizations to accelerate drug and device development. The company supports clients across all phases of clinical development with integrated services spanning study design, patient recruitment, digital trial solutions, and commercialization.

1 investor

IdentiGEN (part of MSD Animal Health) offers technology that combines DNA and data intelligence to provide traceability and lifecycle insights across the animal and food supply chain. It serves food companies, retailers, processors, veterinarians, nutritionists, genetics companies, farm groups, and government bodies.

1 investor

Idience is a biopharmaceutical company focused on developing and commercializing new medicines. Established in 2019 as a wholly owned subsidiary of Korean pharmaceutical group Ildong Holdings.

1 investor

iDose TR is a procedural pharmaceutical implant that delivers travoprost therapy to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The implant uses a proprietary membrane with nanoporous material for controlled drug delivery as an alternative to daily eye drops.

1 investor

iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children. Its initial focus is on neurometabolic and urea cycle disorders, including ornithine transcarbamylase (OTC) deficiency.

1 investor

IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer. The company operates through independently financed R&D subsidiaries, each advancing programs aimed at key control nodes of innate immunity such as NLRP3 and cGAS/STING.

1 investor

IFP Labs operates an integrated network of accredited analytical laboratories in Germany and the UK providing food safety testing, contaminant analysis, and regulatory compliance services. Services span chemical, physical, and microbiological testing for food, feed, water, environmental, and pharmaceutical samples, including nutritional profiling, allergen testing, and label compliance.

1 investor

IGNAE produces a regenerating body oil containing botanical actives and oils designed for skin hydration, collagen stimulation, and repair. The product targets consumers seeking premium skincare solutions for body care.

1 investor

1 investor

IGS develops imaging and visualization technology based on inverse scattering theory to enable observation of previously invisible structures and phenomena. The company applies this core technology to solve problems in medical imaging, energy, infrastructure, and security sectors.

1 investor

Iksuda develops antibody-drug conjugates (ADCs) with enhanced tumor specificity for treating difficult-to-treat cancers. The company designs class-leading ADC therapeutics incorporating novel payloads and platform technologies optimized for anti-cancer efficacy and patient safety.

1 investor

Spaya is an AI-powered retrosynthesis platform that identifies synthetic routes to target compounds by converting them into commercially available starting materials. It serves chemists and drug discovery teams seeking to accelerate research through rapid, customizable synthesis planning.

1 investor